Molecular Mechanisms of Malignant Cerebral Edema After LHI

NCT ID: NCT03703284

Last Updated: 2020-03-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-01

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is to explore the molecular mechanisms underlying the occurrence of malignant cerebral edema (cerebral hernia) after large hemispheric infarction. Acute LHI (\<=48h) patients that develop cerebral hernia or not within 5 days post-stroke onset, as well as the healthy controls will be studied. The participants will be followed for up to 6 months post stroke-onset, and their modified Rankin Scale (mRS) will be recorded. A mRS score of 0-4 is considered as a favorable outcome while a score of 5-6 as an unfavorable one.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of 80 patients with acute large hemispheric infarction (LHI) within 48h after occurrence admitted into NICU of Xuanwu Hospital as well as 40 healthy volunteers will be recruited. The patients' baseline characteristics, treatment and changes of clinical conditions will be recorded, and ICP monitoring (D2-D7 post-stroke), chest X-ray (D2, D7, D14 post-stroke), ECG (D2, D7, D14 post-stroke), cerebral vascular ultrasound, TCD and head MRI (T1WI, T2WI, FLAIR, DWI) on D2 and D14 post-stroke will be performed. Blood samples from both the LHI patients (D2, D4, D7, and D14 post-stroke) and the controls will be analyzed for NEU, TNF-alpha, IL-1b, IL-6, IL-8, IL-17, ICAM-1, VCAM-1, MPO, NE, MMP-9,miRNA, free dsDNA, H3CIT and NETosis levels. All patients were treated for brain edema with osmotic medications-either intravenous 20% mannitol or 10% hypertonic saline. In addition, some patients were treated with decompressive surgery.The patients will be followed up to 6 months and their modified Rankin Scale (mRS) will be recorded. A mRS score of 0-4 is considered as a favorable outcome while a score of 5-6 as an unfavorable one. Statistical differences in the different parameters between different groups at different time points will be analyzed by SPSS 22.0 software.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebral Edema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LHI Hernia

Acute (\<=48h) large hemispheric infarction (LHI) patients who developed cerebral hernia in 5 days post-stroke

Treatments to reduce intracranial pressure

Intervention Type OTHER

Drugs such as mannitol, glycerin fructose, etc and/or surgery

LHI Non-Hernia

Acute (\<=48h) large hemispheric infarction (LHI) patients without cerebral hernia in 5 days post-stroke

Treatments to reduce intracranial pressure

Intervention Type OTHER

Drugs such as mannitol, glycerin fructose, etc and/or surgery

Healthy control

Healthy individuals

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Treatments to reduce intracranial pressure

Drugs such as mannitol, glycerin fructose, etc and/or surgery

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. 18-80 years old;
* 2\. Clinical diagnosis of large hemispheric infarction
* 3\. Within 48h after stroke onset.

Exclusion Criteria

* 1\. Clinical diagnosis of severe infection;
* 2\. Clinical diagnosis of severe heart, liver or kidney diseases;
* 3\. Clinical diagnosis of bleeding tendency, active bleeding or hematological diseases;
* 4\. Malignant tumor;
* 5\. Modified Rankin Scale (mRS)\<2 before stroke onset.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Xuanwu Hospital, Beijing

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yan Zhang

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yan Zhang, M.D., PhD

Role: PRINCIPAL_INVESTIGATOR

Xuanwu Hospital of Capital Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Xuanwu Hospital of Capital Medical University

Beijing, , China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yan Zhang, M.D., PhD

Role: CONTACT

+86 13671376710

Lili Cui, M.D., PhD

Role: CONTACT

+86 13120301056

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Lin-lin Fan, Phd

Role: primary

86-010-83198899 ext. 8424

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LHI

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.